Efficacy of Hemostatic AgentsNCT07058727
Different Hemostatic Agents Used in Partial Pulpotomy on Pulp Survival and Postoperative Pain
A study testing Sodium Hypochlorite 2,5%, Chlorhexidine and Cold Saline in people with Efficacy of Hemostatic Agents and Partial Pulpotomy, run by Cukurova University at 1 site in Turkey (Türkiye).
Trial summary
This randomized clinical trial evaluates the efficacy of sodium hypochlorite (NaOCl), chlorhexidine (CHX), and cold saline as hemostatic agents in partial pulpotomy. The study compares postoperative pain (via VAS scores) and pulp survival (via clinical/radiographic evaluation) at 1, 3, 7 days, 6 months, and 12 months Read more about this study
- Who is it for?
- Ages 15 to 55 years
- Conditions the study is for
- Efficacy of Hemostatic Agents, Partial Pulpotomy, Postoperative Pain
- What is being tested?
- Sodium Hypochlorite 2,5%, Chlorhexidine and Cold Saline
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 75 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 May 2025to 1 May 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 55 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Permanent teeth with carious pulp exposure (no spontaneous pain).
- Positive vitality test (Endo-Ice).
- No periapical radiolucency.
Who cannot join
- Systemic diseases affecting healing.
- Pregnancy.
- Non-vital pulp/necrosis
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Çukurova Üniversitesi Diş Hekimliği Fakültesi
Adana, Sarıçam, 01250
Yaren Coşğun, Dr., +90 544 745 8633, yarenncoskun@gmail.com
About this study
Official title: The Effect of Different Hemostatic Agents Used in Partial Pulpotomy on Pulp Survival and Postoperative Pain: A Randomized Clinical Trial
This randomized clinical trial evaluates the efficacy of sodium hypochlorite (NaOCl), chlorhexidine (CHX), and cold saline as hemostatic agents in partial pulpotomy. The study compares postoperative pain (via VAS scores) and pulp survival (via clinical/radiographic evaluation) at 1, 3, 7 days, 6 months, and 12 months
- Being tested
- Sodium Hypochlorite 2,5%, Chlorhexidine, Cold Saline
- Medical subject headings
- Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sodium Hypochlorite 2,5%Drug
2.5% NaOCl applied for 1 min to exposed pulp for hemostasis, followed by standard pulp capping
ChlorhexidineDrug
2% CHX applied for 1 min to achieve hemostasis, with identical subsequent steps to NaOCl group
Cold SalineDrug
Hemostasis via 4°C saline (1 Min), then standardized pulp capping
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 | Experimental | 2.5% NaOCl applied for 1 min after pulp exposure. Receives: Drug: Sodium Hypochlorite 2,5% |
| Arm 2 | Experimental | 2% CHX applied for 1 min Receives: Drug: Chlorhexidine |
| Arm 3 | Experimental | Hemostasis achieved with 4°C saline for 1 min. Receives: Drug: Cold Saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative Pain
The patient will be asked to rate the pain on the 1st, 3rd and 7th day according to VAS. (The patient is asked to score their pain in this range, with 0 being the lowest and 10 being the highest.)
Measured: 1 week
Pulp Survival Rate
The pulp is expected to be vital, without percussion tenderness and without spontaneous pain
Measured: 12 months
Secondary outcomes (1)
Clinical Success
Maintaining the integrity of the restoration No need for endodontics treatments
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2025
- Study start1 May 2025
- Primary completion1 Nov 2025
- Study completion1 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Efficacy of Hemostatic AgentsStudies of the same condition, open and under way.
- More trials run by Cukurova UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 75 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cukurova University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zehra SUSGUN YILDIRIM, Cukurova University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07058727
- Sponsor's protocol ID
- PP-HemoRCT-2025
- Status last verified
- Mar 2026
- First submitted
- 19 Jun 2025
- Last updated
- 1 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Different Hemostatic Agents Used in Partial Pulpotomy on Pulp Survival and Postoperative Pain: A Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT07058727
- Acronym / sponsor ID
- PP-HemoRCT-2025
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 75 participants (estimated)
- Lead sponsor
- Cukurova UniversityUniversity, hospital or other
- Study start
- 1 May 2025 (actual)
- Primary completion
- 1 Nov 2025 (actual)
- Study completion
- 1 May 2026 (estimated)
- First posted
- 10 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized clinical trial evaluates the efficacy of sodium hypochlorite (NaOCl), chlorhexidine (CHX), and cold saline as hemostatic agents in partial pulpotomy. The study compares postoperative pain (via VAS scores) and pulp survival (via clinical/radiographic evaluation) at 1, 3, 7 days, 6 months, and 12 months
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Arm 1 | Experimental | Drug: Sodium Hypochlorite 2,5%2.5% NaOCl applied for 1 min after pulp exposure. |
| Arm 2 | Experimental | Drug: Chlorhexidine2% CHX applied for 1 min |
| Arm 3 | Experimental | Drug: Cold SalineHemostasis achieved with 4°C saline for 1 min. |
Who may qualify
- Ages
- 15 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (3 listed)
- Permanent teeth with carious pulp exposure (no spontaneous pain).
- Positive vitality test (Endo-Ice).
- No periapical radiolucency.
Key exclusion criteria (3 listed)
- Systemic diseases affecting healing.
- Pregnancy.
- Non-vital pulp/necrosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sodium Hypochlorite 2,5%2.5% NaOCl applied for 1 min to exposed pulp for hemostasis, followed by standard pulp capping | Drug | Arm 1 |
| Chlorhexidine2% CHX applied for 1 min to achieve hemostasis, with identical subsequent steps to NaOCl group | Drug | Arm 2 |
| Cold SalineHemostasis via 4°C saline (1 Min), then standardized pulp capping | Drug | Arm 3 |
Primary outcome
Postoperative Pain
Time frame: 1 week
The patient will be asked to rate the pain on the 1st, 3rd and 7th day according to VAS. (The patient is asked to score their pain in this range, with 0 being the lowest and 10 being the highest.)
Pulp Survival Rate
Time frame: 12 months
The pulp is expected to be vital, without percussion tenderness and without spontaneous pain
1 secondary outcome
Clinical Success
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Apr 2026.
Related trials for Efficacy of Hemostatic Agents
RecruitingPhase 1
Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
AML, Multiple Myeloma
RecruitingPhase 2
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Multiple Myeloma
Active, not recruitingPhase 1/2
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Not yet recruitingPhase 1/2
A Study of MBS314 for Injectionin Participants With Relapsed/Refractory Multiple Myeloma.
Multiple Myeloma
Active, not recruitingPhase 2
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Çukurova Üniversitesi Diş Hekimliği Fakültesi
Adana, Turkey (Türkiye)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sodium Hypochlorite 2,5%, Chlorhexidine and Cold Saline in people with Efficacy of Hemostatic Agents and Partial Pulpotomy, run by Cukurova University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative Pain (time frame: 1 week). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2026.